Development
AbbVie Inc.
ABBV
$191.08
-$1.34-0.70%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -6.44% | -4.64% | -2.31% | 0.03% | 3.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.44% | -4.64% | -2.31% | 0.03% | 3.30% |
| Cost of Revenue | 9.38% | 15.61% | 11.05% | 8.19% | 7.34% |
| Gross Profit | -13.15% | -12.55% | -7.30% | -3.16% | 1.68% |
| SG&A Expenses | 5.91% | 1.94% | 3.10% | 3.00% | 2.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -900.00% | -116.18% | -101.94% | -102.20% | -100.20% |
| Total Operating Expenses | 9.77% | 10.57% | 6.86% | 4.99% | 1.87% |
| Operating Income | -32.83% | -28.03% | -16.36% | -8.01% | 5.72% |
| Income Before Tax | -53.62% | -45.86% | -25.73% | -35.78% | 3.76% |
| Income Tax Expenses | -15.63% | 8.57% | 23.37% | -8.57% | 13.33% |
| Earnings from Continuing Operations | -58.86% | -51.40% | -31.27% | -39.19% | 2.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.11% | 36.36% | 22.22% | 0.00% | -28.57% |
| Net Income | -58.91% | -51.41% | -31.27% | -39.22% | 2.55% |
| EBIT | -32.83% | -28.03% | -16.36% | -8.01% | 5.72% |
| EBITDA | -22.98% | -18.97% | -10.26% | -5.18% | 3.88% |
| EPS Basic | -59.00% | -51.47% | -31.29% | -39.28% | 2.78% |
| Normalized Basic EPS | -33.81% | -28.63% | -15.71% | -7.04% | 8.31% |
| EPS Diluted | -58.85% | -51.30% | -31.22% | -39.34% | 2.69% |
| Normalized Diluted EPS | -33.76% | -28.56% | -15.63% | -7.06% | 8.22% |
| Average Basic Shares Outstanding | -0.18% | -0.10% | -0.03% | -0.07% | -0.06% |
| Average Diluted Shares Outstanding | -0.25% | -0.17% | -0.11% | -0.04% | 0.01% |
| Dividend Per Share | 4.90% | 4.96% | 5.79% | 6.64% | 7.53% |
| Payout Ratio | 1.55% | 1.18% | 0.55% | 0.77% | 0.06% |